301201 诚达药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.1134.0517.76220.34529.765
总资产报酬率 ROA (%)1.0363.8097.08716.50022.424
投入资产回报率 ROIC (%)1.0934.0047.52918.66625.596

边际利润分析
销售毛利率 (%)39.24942.88648.00949.97250.123
营业利润率 (%)16.82126.01930.19628.25037.818
息税前利润/营业总收入 (%)14.19923.29927.87628.38938.856
净利润/营业总收入 (%)15.36921.98925.87824.12032.063

收益指标分析
经营活动净收益/利润总额(%)-0.91660.24871.29797.05868.610
价值变动净收益/利润总额(%)85.68640.11933.0210.0000.000
营业外收支净额/利润总额(%)-5.072-3.404-3.445-1.871-1.120

偿债能力分析
流动比率 (X)9.9299.57816.8761.5292.485
速动比率 (X)9.1618.81715.3050.8241.655
资产负债率 (%)6.5497.1854.55722.4380.141
带息债务/全部投入资本 (%)1.3421.7320.07711.7731.377
股东权益/带息债务 (%)7,338.1895,660.638129,661.467741.6487,076.587
股东权益/负债合计 (%)1,425.7861,290.8642,092.776345.234608.329
利息保障倍数 (X)-7.846-12.503-21.21043.16726.675

营运能力分析
应收账款周转天数 (天)123.604100.94086.13265.54563.461
存货周转天数 (天)223.948218.244219.281140.335120.478